Antibody persistence and response to 2010–2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children

Vaccine ◽  
2011 ◽  
Vol 30 (1) ◽  
pp. 35-41 ◽  
Author(s):  
Vladimir Gilca ◽  
Gaston De Serres ◽  
Marie-Eve Hamelin ◽  
Guy Boivin ◽  
Manale Ouakki ◽  
...  
Keyword(s):  
Single Dose ◽  
Influenza Vaccine ◽  
Pandemic H1n1 ◽  
H1n1 Vaccine ◽  
Antibody Persistence ◽  
Trivalent Influenza Vaccine ◽  
One Year

Improved neutralizing antibody response in the second season after a single dose of pandemic (H1N1) 2009 influenza vaccine in HIV-1-positive adults

Vaccine ◽  
2012 ◽  
Vol 30 (26) ◽  
pp. 3819-3823 ◽  
Author(s):  
Tadashi Kikuchi ◽  
Kiyoko Iwatsuki-Horimoto ◽  
Eisuke Adachi ◽  
Michiko Koga ◽  
Hitomi Nakamura ◽  
...  
Keyword(s):  
Single Dose ◽  
Antibody Response ◽  
Influenza Vaccine ◽  
Neutralizing Antibody ◽  
Pandemic H1n1 ◽  
Pandemic H1n1 2009 ◽  
Hiv 1

scholarly journals Costs per DALYs Averted of Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccine in Elderly Population in Thailand

2021 ◽  
Vol 73 (4) ◽  
pp. 259-267
Author(s):  
Jadesada Lertsirimunkong ◽  
Wiwat Thavornwattanayong ◽  
Panasorn Hirunkanakorn ◽  
Rujipas Buranapatanapong ◽  
Sukanya Jermtienchai ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Cost Effective ◽  
Economic Effects ◽  
Total Cost ◽  
Trivalent Influenza Vaccine ◽  
Incident Rate ◽  
One Year ◽  
The Cost ◽  
Age Over 60 ◽  
Quadrivalent Influenza Vaccine

Objective: Influenza is an infection of the respiratory system with a high annual incident rate. Influenza vaccinecan reduce the severity of influenza and prevent transmission of the virus. Influenza vaccines in Thailand are theTrivalent Influenza Vaccine (TIV) and the Quadrivalent Influenza Vaccine (QIV). The cost and the effectiveness ofthe QIV in preventing transmission of the virus are greater than the TIV. Until now, no studies have been conductedto compare the economic impact of using QIV or TIV. This study aimed to evaluate the economic effects of usingQIV versus TIV in Thai populations age 60 years and over.Materials and Methods: The study was carried out from a societal perspective for cost per DALYs averted. A decisiontree model was used to analyse the costs and DALYs averted of Thais after they received the vaccine.Results: In a period of one year, it was found that in Thais age 60 years and over, the total cost of TIV was 2,445.19baht with 0.0094 DALYs and total cost of the QIV was 2,629.28 baht with 0.0082 DALYs and the incremental costeffectivenessratio (ICER) of the QIV was 158,489.24 baht per DALYs averted. The acceptability curves demonstratedthat the probability of QIV being cost-effective was 95% of the willingness to pay, being 1.2 times the Thai grossnational income per capita.Conclusion: Therefore, in Thai people age over 60 years and over, QIV is more cost-effective than TIV. The resultsof this study can be used by policymakers to help inform their decisions about which influenza vaccine is morecost-effective.

scholarly journals Seasonal Influenza Vaccine Impact on Pandemic H1N1 Vaccine Efficacy

2018 ◽  
Vol 68 (11) ◽  
pp. 1839-1846
Author(s):  
Rachel U Lee ◽  
Christopher J Phillips ◽  
Dennis J Faix
Keyword(s):  
Influenza Vaccine ◽  
Vaccine Efficacy ◽  
Seasonal Influenza ◽  
Pandemic H1n1 ◽  
H1n1 Vaccine ◽  
Seasonal Influenza Vaccine ◽  
Vaccine Impact

scholarly journals Trivalent influenza vaccine in patients on haemodialysis: Impaired seroresponse with differences for A-H3N2 and A-H1N1 vaccine components

Vaccine ◽  
1987 ◽  
Vol 5 (1) ◽  
pp. 43-48 ◽  
Author(s):  
W.E.P. Beyer ◽  
D.J. Versluis ◽  
P. Kramer ◽  
Ph.P.M.N. Diderich ◽  
W. Weimar ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
H1n1 Vaccine ◽  
Trivalent Influenza Vaccine

Influenza Vaccination and Intention to Receive the Pandemic H1N1 Influenza Vaccine among Healthcare Workers of British Columbia, Canada: A Cross-Sectional Study

2010 ◽  
Vol 31 (10) ◽  
pp. 1017-1024 ◽  
Author(s):  
Fariba Kaboli ◽  
George Astrakianakis ◽  
Guiyun Li ◽  
Jaime Guzman ◽  
Monika Naus ◽  
...  
Keyword(s):  
British Columbia ◽  
Influenza Vaccine ◽  
Healthcare Workers ◽  
Seasonal Influenza ◽  
H1n1 Influenza ◽  
Pandemic H1n1 ◽  
Cross Sectional ◽  
H1n1 Vaccine ◽  
Pandemic H1n1 Influenza ◽  
To Receive

Objective.To assess healthcare workers' attitudes and concerns regarding seasonal and pandemic influenza vaccines in order to improve vaccination campaign communications.Design.Cross-sectional survey.Setting.All 6 health authorities in British Columbia, Canada.Methods.An anonymous, self-administered online survey was conducted from August 30 through September 30, 2009. Question topics included demographic characteristics, factors influencing acceptance of seasonal influenza vaccine, factors influencing intentions to accept pandemic H1N1 influenza vaccine, and knowledge and concerns regarding the effect of the influenza pandemic.Participants.All 96,217 British Columbia healthcare workers were eligible to participate.Results.A volunteer sample of 4,046 healthcare workers returned the survey; 3,563 (88%) were women, 58% were under 50 years old (mean age ± standard deviation, 45.3 ± 10.9 years), 3,152 of 4,023 (79%) had 5 or more years of experience in their profession, 1,853 of 4,023 (46%) were nurses, and 2,833 (70%) had been vaccinated against seasonal influenza the previous year. Two thousand eight hundred (69%) respondents reported intending to receive the pandemic H1N1 vaccine. The most important predictor of this intention was having received the seasonal vaccine the previous year (odds ratio [OR], 6.25 [95% confidence interval {CI}, 5.39-7.26]). Worry about making loved ones ill was the only attitude associated with intention to receive the pandemic H1N1 vaccine (adjusted OR, 1.38 [95% CI, 1.27-1.50]). Concerns with vaccine safety (adjusted OR, 0.31 [95% CI, 0.25-0.39]) and belief “that H1N1 is not severe enough” (adjusted OR, 0.29 [95% CI, 0.26-0.32]) were independently associated with the intention to reject the pandemic H1N1 vaccine.Conclusions.Vaccination campaigns for pandemic H1N1 vaccine should use messages that emphasize the risk of illness among younger people and the opportunity to protect loved ones by getting the vaccine and should address concerns about the safety and effectiveness of the vaccine.

scholarly journals Efficacy of a trivalent influenza vaccine against seasonal strains and against 2009 pandemic H1N1: A randomized, placebo-controlled trial

Vaccine ◽  
2016 ◽  
Vol 34 (41) ◽  
pp. 4991-4997 ◽  
Author(s):  
William J.H. Mcbride ◽  
Walter P. Abhayaratna ◽  
Ian Barr ◽  
Robert Booy ◽  
Jonathan Carapetis ◽  
...  
Keyword(s):  
Influenza Vaccine ◽  
Controlled Trial ◽  
Pandemic H1n1 ◽  
Trivalent Influenza Vaccine

The Pandemic H1N1 Influenza Vaccine Results In Low Rates of Seroconversion In Patients with Hematological Malignancies

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3110-3110
Author(s):  
Katherine Monkman ◽  
James Mahony ◽  
Alejandro Lazo-Langner ◽  
Benjamin Chin-Yee ◽  
Leonard A. Minuk
Keyword(s):  
Influenza Vaccine ◽  
Hematological Malignancies ◽  
Geometric Mean ◽  
H1n1 Influenza ◽  
Pandemic H1n1 ◽  
Plasma Samples ◽  
H1n1 Vaccine ◽  
Post Vaccination ◽  
Fourfold Increase ◽  
Antibody Titres

Abstract Abstract 3110 Background: Patients with hematological malignancies are at increased risk of influenza and its complications. However, evidence for the efficacy of influenza vaccination in this population is limited and contradictory [Pollyea et al., J Clin Oncol. 2010]. The adjuvanted pandemic H1N1 vaccine has been shown to be highly effective in healthy adults, with reported rates of seroprotection and seroconversion of over 90% [Plennevaux et al., Lancet 2010]. We sought to determine whether patients being treated for hematological malignancies were able to mount a protective antibody response to the H1N1 pandemic influenza vaccine. Methods: Patients being treated for hematological malignancies at the London Regional Cancer Program during the 2009–2010 influenza season were invited to participate. Patients who had received the vaccine prior to the commencement of the study in November 2009 were excluded. Pre-vaccination plasma samples were collected in November 2009, and post-vaccination samples were collected from January through March 2010. At the time of second sample collection, patients were asked to complete a questionnaire asking if and when they had received the H1N1 influenza vaccine. Plasma samples from patients who elected not to be vaccinated formed a control group. Antibody titration was performed by the hemagglutinin inhibition test. Our primary outcome was the rate of seroconversion, as defined by a fourfold increase in antibody titres. We also measured geometric mean titres (GMT), geometric mean titre ratios, (GMTR, defined as the ratio of the post-vaccination titre to the pre-vaccination titre), and rates of seroprotection (titre ≥ 1:80). Statistical analysis was done using Mann-Whitney U, chi-squared, or Fisher's Exact Tests, as appropriate. Results: Sixty-two patients received the H1N1 vaccine and 41 patients chose not to be vaccinated. The rate of seroconversion among vaccinated patients was 21%, which was significantly higher than that in unvaccinated patients (0%) and significantly lower than that in healthy individuals. The GMTR was significantly higher in the vaccinated group than the unvaccinated group (2.2 ± 2.5 vs. 1.2 ± 0.6, p = 0.041). There were no significant differences in the geometric mean titres or the rates of seroprotection between the vaccinated and unvaccinated groups. Of the 46 patients on active chemotherapy who received the vaccine, 10 (22%) seroconverted and 16 (35%) mounted seroprotective titres. Of the 12 patients on active Rituximab who received the vaccine, 2 (17%) seroconverted and 4 (33%) mounted seroprotective titres. There were no significant differences in the rates of seroconversion and seroprotection between patients on or off chemotherapy or between patients on or off Rituximab. Conclusions: Only 21% of patients with hematological malignancies were able to produce a fourfold increase in antibody titres in response to the H1N1 influenza vaccine, a rate significantly lower than that previously reported for healthy patients. We were unable to identify any clinical factors predictive of a response to the vaccine. Physicians should be aware that patients with hematological malignancies are less likely to receive protection from the influenza vaccine, and should consider alternate strategies to minimize the morbidity and mortality from influenza in this population. Larger studies are indicated to confirm these results. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document